VOLUME 37 | ISSUE 4 | JULY-AUGUST 2017

Erratum Font size: Decrease font Enlarge font

Erratum

Ann Saudi Med

In Ann Saudi Med 2016; 36(3) 190-196: “Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor”, “Basel M. Albattal” should not have been the author of the article. Instead, the following are the correct authors and their affiliations:

 

Omer Ahmad Fatheddin Abdulkader,a Khalid Qushmaq,b Faiza Aljishic

 

From aKing Abdul-Aziz University Hospital, Jeddah, Saudi Arabia; bKing Fahad Medical City, Riyadh, Saudi Arabia; cKing Fahad Specialist Hospital, Dammam, Saudi Arabia

 

In addition, the following statements regarding the source of funding and acknowledgements should have been included:

 

ROLE OF FUNDING SOURCE 

This study was sponsored and funded by Hoffmann-La Roche Ltd through the supply of medication as it was not bought by the treating hospitals. We would like to declare that Hoffmann-La Roche Ltd initiated the study (Concept and Protocol Synopsis).

 

 

ACKNOWLEDGMENT

We thank all the study participants and Basel Al-Battal, Senior Medical Manager for Rheumatoid Arthritis in Hoffmann-La Roche Ltd, for his initiatives.

 

 

In this article

Submit Your Manuscript Here:

Indexed in:

Advertisement Medium Rectangle Ad 1

Do you want your Ad here? Contact Us

Social

LinkedIn
cron